The alcohol withdrawal syndrome is a well-known condition occurring after intentional or unintentional abrupt cessation of heavy/constant drinking in patients suffering from alcohol use disorders (AUDs). AUDs are common in neurological departments with patients admitted for coma, epileptic seizures, dementia, polyneuropathy, and gait disturbances. Nonetheless, diagnosis and treatment are often delayed until dramatic symptoms occur. The purpose of this review is to increase the awareness of the early clinical manifestations of AWS and the appropriate identification and management of this important condition in a neurological setting.
zone of these seizures is distinct from that believed to be responsible for seizures in the context of epilepsy, and this may explain why epileptiform activity is rarely observed in the EEG after alcohol withdrawal seizures. 8 As upregulation of NMDA receptors as well as reduced GABA-A receptor inhibition largely explain the clinical symptoms, the therapeutic approach to AWS mainly targets these mechanisms.
Dopamine is another neurotransmitter involved in alcohol withdrawal
states. During alcohol use, increase in dopamine positively influences the reward system thereby maintaining abuse. In withdrawal, increase in dopamine levels contributes to the clinical manifestations of autonomic hyperarousal and hallucinations. 10, 11 Moreover, polymorphisms in the dopamine receptor 2 gene seem to influence not only AUD but also the clinical manifestation of alcohol withdrawal symptoms. 12 In combination with increased glutamate and norepinephrine, it may also cause the elongation of the QT interval in people who have active epilepsy; this can increase the risk of sudden unexpected death in epilepsy (SUDEP). 9 Another excitotoxic compound that is increased in AUD is homocysteine. During active drinking, there is an increase in homocysteine through stimulation of the NMDA receptors. In withdrawal, excitotoxicity is induced by further raise in homocysteine via rebound activation of glutamatergic neurotransmission. 
| CLINICAL SPECTRUM
AWS represents a group of symptoms that usually arise 1-3 d after the last drink. Sometimes, the symptoms are already present when the alcohol blood level is above 0 (0.5‰ or even more).
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The Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
outlines diagnostic criteria for AWS using two main components so that the AWS is diagnosed when the following two conditions are met: 
2.
The symptoms of withdrawal are not accounted for by a medical or another mental or behavioral disorder.
Physical examination and investigations should be directed toward detecting common signs and symptoms of AWS that are listed in Table 1 .
6,10,14-18
The alcohol withdrawal syndrome is a dynamic and complex process. For this reason, there have been many attempts to classify symptoms of AWS either by severity or time of onset to facilitate prediction and outcome. In early stages, symptoms usually are restricted to autonomic presentations, tremor, hyperactivity, insomnia, and headache.
In minor withdrawal, patients always have intact orientation and are fully conscious. Symptoms start around 6 h after cessation or decrease in intake and last up to 4-48 h (early withdrawal). 6, 10 Hallucinations of visual, tactile or auditory qualities, and illusions while conscious are symptoms of moderate withdrawal. They can last up to 6 d. The appearance of acute symptomatic seizures may emerge 6-48 h after the last drink. 19 Delirium tremens (DT, onset 48-72 h after cessation of drinking) represents characteristics of severe withdrawal that may last for up to 2 weeks (late withdrawal). 6, 10, 15, 18 The chronological development of the various symptoms is illustrated in Fig. 1 .
The alcohol withdrawal seizure is a symptom occurring primarily during the early phase of withdrawal and is characterized by reduction in the seizure threshold. More than 90% of acute symptomatic seizures emerge within 48 h of cessation of prolonged drinking. 20, 21 Seizures frequently occur in the absence of other signs of the AWS.
More than half of the individuals present with repeated seizures, and in up to 5%, they may progress to status epilepticus. 17 More than 50% of withdrawal seizures are associated with concurrent risk factors such as prior epilepsy, structural brain lesions, or use of other drugs. 17, 20 It is remarkable that the development of acute symptomatic seizures during an alcohol withdrawal episode is associated with a fourfold increase in the mortality rate that is due to complications of severe Delirium is a clinical syndrome of acute onset characterized by a global confusional state, perceptual abnormalities, and somatic symptoms of vegetative or central nervous presentation. 6 Hallucinosis represents a unique form of withdrawal-related psychosis which can begin even while the person is continuing to use alcohol or after cessation of drinking. The sensorium is clear in the beginning, but it often evolves into the syndrome of DT, a specific type of delirium typically associated with psychomotor agitation (hyperactive delirium) which emerges during the late withdrawal phase. 14, 18 Delirium can also manifest as a hypoactive state with decreased arousal and psychomotor activity, which is associated with a worse prognosis, delayed diagnosis and treatment as well as later complications. 6 In cases of hypoactive delirium, comorbid or other medical illnesses must be ruled out. This is especially important in patients who have not had a previous history of DT. Differential diagnoses for severe alcohol withdrawal are listed in Table 2 . 10, 15 In summary, physical examination and investigations should be directed toward detecting signs of intoxication, seizures, hallucinations, and delirium tremens as well as Wernicke's encephalopathy (one or more symptoms of ataxia, amnesia, and ophthalmoplegia). Apart from neuropsychiatric symptoms, physical injury or medical problems including aspiration pneumonia, dehydration, and electrolyte imbalance should be taken into account. 16 
| BIOMARKERS
In several studies, possible predictors for the development of a se- 
| Markers useful in the emergency setting
The quantitative, measurable detection of drinking is important for the successful treatment of AUD. Therefore, the importance of direct and indirect alcohol markers to evaluate consumption in the acute clinical setting is increasingly recognized. A summary of relevant markers in the emergency setting is given in Table 3 . The detection of ethanol itself in different specimens is still a common diagnostic tool to prove alcohol consumption. Alcohol ingestion can be measured using a breath test. Although ethanol is rapidly eliminated from the circulation, the time for detection by breath analysis is dependent on the amount of Apart from ethanol itself, indirect markers of AUD are widely available and mostly part of routine laboratory testing. Severe AWS involves changes in electrolytes, especially potassium that is due to increased catecholamine activity with activation of the sodium-potassium ATPase pump and elevated vasopressin. 25 Hypokalemia is not specific for alcohol consumption but is frequently reported to be associated with DT or seizures. 10, 25, 28, 29 The same applies to thrombocytopenia (with high negative predictive value) 10, 24, 25, 29, 30 that additionally is predictive of an incident occurrence of DT and seizures. 25 More indirect markers, such as AST, ALT, γGT, and MCV, are widely available and relatively inexpensive, but their predictive value is restricted because of low specificity. The interpretation of elevated values has to take into account other influencing factors including gender, age, comorbid disorders, and medication that also may increase these markers. 
| Additional markers to detect AUD
Further biomarkers for non-emergency cases or in the event of forensic questions are listed in Table 4 . Carbohydrate-deficient transferrin (CDT) is the most available and studied biomarker and has a high specificity for severe AUD. coconjugate metabolites. 30 The highest sensitivity of up to 99% was observed for Peth 31, 41 that showed a rapid decrease at the beginning of withdrawal, a slow decline after the first few days, and persistence at low levels beyond 19d of abstinence. 42 Apart from biomarkers detected in blood and urine samples, saliva is a promising and easy accessible material to detect glycomarkers of oxidative stress, 43, 44 but the reproducibility and validity in Peth has to be proven for clinical routine application. 45 As an antibody based flash test is available for detection of EtG in urine with good sensitivity and specificity, this parameter is the most promising one to be integrated in routine laboratory settings and in screening of patients at risk to develop AWS.
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As long as ethanol is metabolized, the metabolism of serotonin is shifted from formation of 5-hydroxyindole-3-acetic acid (5-HIAA) toward 5-hydroxytryptophol (5-HTOL). The 5-HTOL/5-HIAA ratio increases appreciably in urine after alcohol intake and is a promising marker for recent alcohol intake with a short window of detection.
Until now, it has not found its way into clinical routine because of costly detection assays. 47, 48 Recent investigations pointed out that homocysteine levels on admission might be a useful screening method for the risk of seizures in AWS, particular in combination with CDT. 41 question. An overall total score of ≥3 is FAST positive.
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The CAGE screening test has a similar goal as FAST, which is to identify AUD thereby increasing the detection rate in chronic alcoholics. The name CAGE is an acronym of its four questions: feeling need to Cut down; Annoyed by criticism; Guilty about drinking; and need for an "Eye-opener" in the morning. The questions relate to the whole of the patient's life, not just to the current circumstances. A total score of ≥ 2 is considered clinically significant with a specificity of 77% and sensitivity of 91% for the identification of AUD.
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The TWEAK is an acronym of the first letter of the key words in the questions of this screening tool: Tolerance, Worried, Eye-opener, Amnesia, K (cutdown) and represents a modification of the CAGE. An answer of ≥ 6 to the first question or a total score of ≥ 3 denotes an AUD. The TWEAK has to be found to be superior to CAGE in screening pregnant women. 61 The main disadvantage of these tests is their dependence on the cooperation, comprehension, self-reflexion, and honesty of the patient. 
| Questionnaires to predict AWS
The PAWSS (Prediction of Alcohol Withdrawal Severity Scale) is the first validated tool to identify patients at risk for complicated alcohol withdrawal (seizures and DT), allowing for prophylaxis against AWS before severe alcohol withdrawal symptoms occur. The first pilot studies showed sensitivity, specificity, and positive and negative predictive values of 100%, using the threshold score of four. The PAWSS represents a new tool helping clinicians to identify those patients at risk for developing severe AWS and allowing for timely prophylactic treatment. 62 
| Questionnaires to detect severity of AWS
Once a patient has been diagnosed with AWS according to DSM-5, it is necessary to assess their baseline severity of symptoms to Other scales, including the Alcohol Withdrawal Scale, have been developed that require less reliance on patients' response and that cover the whole spectrum of withdrawal syndromes including delirium. The Alcohol Withdrawal Scale is based on a factor-analyzed version of the CIWA-A-Scale and consists of six vegetative (pulse rate, diastolic blood pressure, body temperature, breathing rate, sweating, and tremor), and five mental or psychopathological symptom items (agitation, anxiety, tactile disturbances, disorientation, and hallucinations) each of which are operationalized. 14 Using these two dimen- 
| NEUROIMAGING
Neuroimaging is recommended to exclude other neurological conditions especially in cases with first onset seizures/status epilepticus (SE), as these are associated with concurrent risk factors in >50%.
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Moreover, it is important to identify SE or seizure-related neuroimaging features. Such findings can mimic those of acute ischemic stroke, but are not restricted to vascular territories. The most frequent seizure-related MRI abnormalities are hyperperfusion and cortical hyperintensities with corresponding low apparent diffusion coefficient, in CT areas of decreased attenuation, an effacement of sulci and loss of gray-white differentiation. 66 Mainly affected structures are hippocampus, amygdala, medial thalamus, and the cerebral cortex. 17, 67 Follow-up examinations usually show complete or partial resolution of these abnormalities. 68 or a decreased power in theta and delta waves and an increase in beta bands, the last one often due to BZD medication. 

| ELECTROENCEPHALOGRAM
| Strategies for the use of BDZ
Multiple dosing strategies have been utilized in the management of AWS. When using any dosing technique, it is important to recognize the symptoms of benzodiazepine toxicity that can include respiratory depression, excessive sedation, ataxia, confusion, memory impairment, and delirium, which may be difficult to differentiate from DT .
| Loading dose regimen
The "front-loading" or "loading dose" strategy uses high doses of longer-acting benzodiazepines to quickly achieve initial sedation with a self-tapering effect over time due to their pharmacokinetic properties. Typically, diazepam 10-20 mg or chlordiazepoxide 100 mg doses are repeated every 1-2 h until the patient reaches adequate sedation with an average of three doses usually required. 3 Studies found diazepam loading to significantly reduce the risk of complications, to reduce the total dose of benzodiazepines needed, and the duration of withdrawal symptoms. A further benefit of this approach is that intensive monitoring and medication administration are limited to the early period of withdrawal. 3, 75 As the loading dose regimen may cause sedation and respiratory depression, withdrawal severity and the clinical condition need to be monitored prior to each dose to avoid benzodiazepine toxicity. This is especially important in elderly patients and those with hepatic dysfunction.
| Fixed-dose application
The "fixed-dose" technique implies that a certain amount of medication is administered at regular intervals. This approach may be beneficial for patients who will require medication regardless of symptoms, such as in those with a history of seizures or DT. 
| Symptom-triggered treatment
For this approach to be successful, patients must be symptomatic and there must be regular assessment of patient's withdrawal symptoms using a validated tool like the CIWA-Ar scale. Therefore, this regimen requires close monitoring. For this reason, the technique is not applicable in non-verbal patients, and it is not safe in patients with a past history of withdrawal seizures because they can occur even without AWS symptoms. are associated with higher mortality due to cardiac arrhythmia by F I G U R E 2 Clinical workflow of diagnosis and therapy of AWS prolongation of the QT interval. Furthermore, they lower the seizure threshold. Therefore, antipsychotic agents should be used cautiously in AWS, particularly in its early stage (<48 h) when the seizure risk is high (Fig. 1) However, because of the study design and the lack of comparison to BZD, the study did not support implementation into clinical routine. 81 Concerning gabapentin, there were similar results with some effects on mild/moderate withdrawal symptoms but no superiority to BZD. treatment still needs to be investigated. 83, 84 In summary, besides BZD, anticonvulsants seem to be widely used for the treatment of AWS. Nevertheless, a Cochrane review investigating 56 studies with a total of 4076 participants found no sufficient evidence in favor of any antiepileptic agent for therapy of AWS. 
| Alpha-2 agonistic agents
Dexmedetomidine (DEX), a more potent ɑ-2 agonist than clonidine, decreases sympathetic overdrive and release of norepinephrine. Due to its rapid onset of action and short half-life, it produces a "cooperative sedation" without necessity for intubation. As ɑ-2 agonists lack the GABAergic activity to prevent and treat DT or seizures, they can only be used as adjunctive therapy to reduce autonomic hyperactivity that cannot be controlled by BZD alone. 3, 80, 86 Several studies demonstrated a BZD-sparing effect with significant reduction in BZD requirement.
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| Anesthetic agents
Propofol
Propofol enhances the inhibitory effects at the GABA-A receptor and decreases excitatory circuits of the NMDA transmitter system. Due to its strong lipophilic properties, it features a rapid onset of action and is easy to titrate because of the short half-life. Propofol has general anesthetic effects that often require intubation and mechanical ventilation. Its use is therefore restricted to the intensive care unit making this agent an adjunct therapy for refractory cases of AWS. 3, 6, 80, 90, 91 Its application and experience in AWS is limited to only a few cases and rebound of withdrawal symptoms soon after stopping propofol infusion has been reported.
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Barbiturates
Barbiturates are also GABA-enhancing drugs that work synergistically with BZD featuring a different receptor profile. They can be given orally or intravenously with a loading dose of 100-200 mg/h and have been shown to be as effective as BZD. 92 Unfortunately, barbiturates have a narrow therapeutic index with a long half-live making titration difficult. They increase the likelihood of respiratory insufficiency and coma so that intubation and mechanical ventilation is often necessary.
Because there is no antidote to toxicity, barbiturates are not used frequently in the therapy of AWS. Further side effects of clomethiazole are an increased risk of pneumonia due to bronchial mucus accumulation as well as dependence, so that administration should not exceed 10 d. 6, 93 Moreover, clomethiazole is subjected to a pronounced first pass effect by the isoenzyme CYP2E1 which is blocked by ethanol consumption. Accordingly, the combinatory intake of clomethiazole and ethanol should be avoided due to its possible life-threatening effects.
| Gamma-hydroxybutyric acid (GHB) and Sodium oxybate (SMO)
GHB, admitted to the treatment of narcolepsy, is an endogenous neurotransmitter and a metabolite of GABA. It has a stake in GABAdependent neurotransmission, dopamine release, and thereby, it regulates the wake-sleep cycle. GHB acts as a depressant at higher doses and has anxiolytic properties. 94 A Cochrane review shows impact on symptoms of alcohol withdrawal in comparison with placebo, but no superiority to BZDs or clomethiazole in prevention of AWS with a high risk of misuse, abuse, and addiction. 95 SMO is the sodium salt of γ-hydroxybutyric acid, a naturally occurring short-chain fatty acid that is structurally similar to GABA. In addition to the activation of the GABA-A receptor, it has also alcohol mimicking effects due to dopamine release in the CNS. 3 There are some studies showing SMO to be equally effective as BZD in moderate-to-severe AWS. 96, 97 When used for a short period, SMO is relatively well tolerated; in long-term use, there is, as is known for GHB, concern about abuse and dependence based on its euphoric properties. 
| ADJUNCTIVE THERAPEUTIC AGENTS
| Magnesium
Magnesium is an important cofactor of many enzymes and acts as an inhibitor of neurotransmitter release. Therefore, it may dampen the NMDA-driven hyperexcitability in AWS by competing with glutamate in its receptor binding site. Furthermore, magnesium impedes the NO synthase and calcium-dependent channels, lowering action potential firing. 100 As chronic alcohol use is associated with abnormal magnesium metabolism, patients have been given magnesium to treat or prevent AWS. 10 Based on a Cochrane review, there is currently insufficient evidence to support the routine use of magnesium for prophylaxis or treatment of AWS. 101 Nevertheless, as alcohol use and withdrawal are connected with QT interval prolongation and cardiac arrhythmia, 102 laboratory values of magnesium should be determined and deficiencies be balanced.
| Thiamine
Wernicke's encephalopathy (WE) is afflicted with high morbidity and mortality and presents only in rare cases with the classic triad of confusion, ataxia, and ophthalmoplegia. 10 According to the EFNS guideline for diagnosis of WE, two of the following four signs are required: (i) dietary deficiencies, (ii) eye signs, (iii) cerebellar dysfunction, and (iv) either an altered mental state or mild memory impairment.
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Particularly in severe AWS with predominant symptoms of DT, differentiation from WE is sometimes impossible. Because of its easy and uncomplicated treatment, prevention of WE with parenteral thiamine should be performed in all patients at risk, including those experiencing AWS and prior to any parenteral carbohydrate-containing fluids. 10, 16 The earlier thiamine supplementation is started, the faster is recovery, regardless of initial clinical presentation. 
| Search Strategy and Selection Criteria
References for this review were identified by searches of PubMed between 1985 and 2016, and references from relevant articles. The search terms "alcohol withdrawal," "alcohol withdrawal seizures,"
"alcohol withdrawal diagnosis," "alcohol withdrawal therapy,"
"alcohol abstinence syndrome," "abstinence treatment," "delirium tremens," "alcohol withdrawal EEG," and "alcohol withdrawal MRI"
were used. There were no language restrictions. The final reference list was generated on the basis of relevance to the topics covered in this review.
